Thus, we here developed a new mechanistic quantitative systems pharmacology model that integrates ErbB signaling networks in HER2+ BC cells, pharmacokinetics of different state-of-the-art drug modalities, as well as mechanisms of drug-induced cellular perturbations and tumor growth to facilitate drug development and translation. This evidence concerns the gene ERBB2 and breast cancer.